Lifetime Medendi Virtual Hospital & Medendi AI Platform
Business Plan 2026/2030
Transforming precision oncology through the integration of innovative clinical services and advanced artificial intelligence
Corporate Structure: Lifetime Srl currently holds 100% of Medendi AI Srl
Lifetime Srl, as the operating holding company and owner of the Medendi brand, holds the regulatory authorizations necessary for the provision of healthcare services in Italy (B2C)
Medendi AI Srl ensures full strategic and operational integration, optimizing the execution of our mission and maximizing business value through consolidated synergies. (B2B)
Table of Contents
Navigate through the key sections of the 2026/2030 Business Plan for a complete overview
Executive Summary
Summary of company objectives and strategies.
The Team and the Scientific Committee
Presentation of the talents driving our vision.
The Market
In-depth analysis of the industry and growth opportunities.
The Problem
Identification of current challenges in the oncology sector.
The Solution
Our innovative approach and the Medendi AI platform.
The Target Customer
Definition and segmentation of our ideal users.
Business Model
Monetization strategies and value generation.
Go-to-Market
Plans and strategies for product launch and dissemination.
The Competitors
Analysis of the competitive landscape and our positioning.
Funding Request
Details on the funding request and use of funds.
Business Plan
Financial projections and detailed operations.
Return on Investment
Evaluation of potential benefits for investors.
Executive Summary
Lifetime Medendi
Virtual Hospital + AI Platform for Precision Oncology
The Problem
Traditional oncology is slow and fragmented, with manual research covering less than 50% of relevant evidence. In Italy, only ~2% of biopsies receive extended NGS compared to the European average of 10%, leading to wasted time and suboptimal therapies.
The Solution
We industrialize clinical precision with an end-to-end pathway: NGS up to ~700 genes, proteomics, and MRD on ctDNA, finalized by an international Molecular Tumor Board within 48–72 hours with an operative digital report.
The AI Engine
Medendi AI_D is a Class IIb CE MDR SaMD with XAI by design. It integrates 4.5M publications, 380K trials, 42 genomic databases, 120K patients, and ~6,800 drugs with proprietary AI algorithms.
Business Model
B2C Premium: 3–5K package per patient including MTB
B2B SaaS Enterprise:
  • License 50K EU / 80K USA per hospital
  • Fee per case: 150 EU / 400 USA
  • MTB on-demand: 1.9K
  • Software margins >50% when fully operational
Economics & ROI
19,59M
2030 Revenues
CAGR 106%
59,4%
EBITDA Margin
11.63M by 2030
126M
B2B Equity Value
AI Valuation
Round: 1.2M
v 1.0 platform, MDR/FDA certifications, healthcare go-to-market, key hires
EU Financial Projection: Breakeven and Beyond
Positive cash flow 2026, positive EBT 2027
USA Expansion
Infrastructure scaling and clinical pilot studies

Strategic Exit Options
Pharma and Biotech: Accelerate drug development and personalized medicine through biomarker-driven decision support.
Diagnostics and Laboratory Networks: Revolutionize diagnostics and optimize therapeutic efficacy with guided therapies.
CROs and RWE Platforms: Transform clinical research and the application of real-world data for real-time evidence.
Private Hospital Groups: Optimize patient care and operational efficiency by standardizing multi-site Molecular Tumor Boards.
Two Synergistic Solutions to Revolutionize Precision Oncology
B2C: Lifetime Medendi Hospital
Lifetime Medendi is a virtual hospital specializing in precision oncology, offering advanced diagnostic services and rapid consultations. It provides extensive genomic profiling (up to ~700 genes), proteomic analyses, minimal residual disease (MRD) monitoring, and germline genetic testing.
This data converges into a world-class digital Molecular Tumor Board, which formulates personalized therapeutic recommendations within 48-72 hours. Thanks to an international scientific committee and cutting-edge diagnostic technologies, Medendi ensures every patient receives the best available therapeutic options.
B2B: Medendi AI_D Platform
Medendi AI_D is an AI-based SaMD platform for clinical decision support.
It analyzes clinical and molecular data in real-time, guiding oncologists in selecting optimal targeted therapies. It standardizes genetic interpretation, updates recommendations with scientific evidence, reducing reporting times and improving decisions.
Lifetime Srl, through its control of Medendi AI Srl, ensures full integration between clinical practice and technology.

In summary: Lifetime Medendi combines the direct provision of innovative clinical services (B2C) with the commercialization of a proprietary AI-based platform (B2B), creating unique synergies to make precision oncology more accessible, personalized, and sustainable for an increasing number of patients.
The Team
An exceptional team that combines clinical expertise, entrepreneurial vision, and technological innovation to redefine oncology.
Maurizio Scaltriti
Head of the Scientific Committee and Founder. An internationally renowned researcher, specialized in oncology and molecularly targeted therapies. Currently Vice President of Translational Medicine in Oncology at AstraZeneca.
Giorgio Pasetto
Medical Director and Co-founder. Physician and entrepreneur, specialized in territorial emergency medicine. He has developed innovative solutions to improve healthcare, with a focus on oncology.
Fotios Loupakis
Scientific Director. An internationally renowned oncologist, he coordinated translational research on gastrointestinal tumors at the Veneto Institute of Oncology and the University Hospital of Pisa.
Cristian Massacesi
CMO at Medendi. EVP, CMO and Head of Development, Bristol Myers Squibb with over 20 years of experience in oncology drug development.
Davide Barbieri
Data Scientist: Expert in artificial intelligence and data science, with academic and professional experience in the sector.
Saverio Patruno
Software Engineer: Expert in artificial intelligence. He oversees the engineering of robust pipelines, HL7/FHIR integration, security, and real-time performance.
Marco Amato
Entrepreneur and CTO with 20 years of experience and a strong technical and technological background. He has founded/co-founded companies that achieved exit with national and international groups.
Roberto Gallosti
CEO at Medendi A visionary leader and healthcare executive with proven experience, Roberto drives the strategic transformation of medical centers, ensuring excellence in the management of accredited clinics and a significant impact on business growth.
Scientific Committee
A network of international prestige comprising leading experts in precision oncology, translational research, and cancer genomics. Our Scientific Committee ensures Medendi's clinical and scientific excellence, bringing expertise from the world's most important research centers.
Debyani Chakravarty
Molecular geneticist, principal scientist at OncoKB, expert in cancer genomics and targeted therapies.
Joaquín Mateo
Oncologist specializing in advanced prostate cancer and precision oncology, with a focus on translational research.
Aleix Prat
Oncologist specializing in breast cancer and tumor genomics. Co-founder of Reveal Genomics (HER2DX®) for therapeutic personalization.
Giuseppe Curigliano
Internationally renowned oncologist, Director of Early Drug Development (IEO Milan). ESMO President-Elect.
Fotios Loupakis
Oncologist and researcher specializing in gastrointestinal tumors. Therapeutic Area Lead at AstraZeneca Italy and Scientific Director of Medendi.
Alexander Drilon
Oncologist specializing in targeted therapies for lung cancer. Chief of the Early Drug Development Service at MSKCC.
Sandra P. D'Angelo
Oncologist specializing in sarcomas and Merkel cell carcinoma. Expert in immunotherapy and innovative therapies for rare tumors.
Daniele Generali
Oncologist specializing in female cancers, Head of Breast Pathology and Translational Research at ASST of Cremona.
Aviram Mizrachi
Surgeon specializing in head and neck oncology, Associate Professor at Weill Cornell Medical College.
Camillo Porta
Full Professor of Medical Oncology at the University of Bari. Recognized authority in the treatment of renal tumors.
Jaume Mora Graupera
Pediatric oncologist specializing in developmental tumors, Scientific Director of Oncology and Hematology at Hospital Sant Joan de Déu.
Giannicola Genovese
Oncologist and researcher specializing in cancer genomics. Associate Professor at MD Anderson Cancer Center.
The Market
A Vast Unmet Need
B2C: Patient Market
The target market includes oncology patients with advanced-stage or rare cancers who can particularly benefit from personalized therapies. In Italy, approximately 390,000 new cancer cases are diagnosed annually, but access to advanced molecular testing and multidisciplinary consultations remains limited.
  • Only ~2% of biopsies analyzed with NGS (vs. 10% EU average)
  • Growing segment willing to invest in qualified second opinions
  • Regional public MTB networks under implementation
B2B: Global Market
Globally, the volume of clinical and scientific data in oncology is exploding – with nearly 29,000 oncology clinical trials underway by 2025 – making it increasingly complex for hospitals to keep pace with new evidence.
  • Specialized hospitals and oncology centers
  • Large multi-site hospital groups
  • Global market: Italy → Europe → USA → Asia
Our private service complements (rather than conflicts with) the public system, quickly and expertly covering areas where public services struggle to reach. The addressable B2B market is broad and global, with thousands of potential target structures in the medium to long term and an adoption propensity destined to grow as precision oncology becomes the new standard of care.
The Problem
Critical Barriers to Accessing Precision Oncology
For Patients (B2C)
For those facing cancer, every day counts. Unfortunately, the journey for advanced oncology patients is still too often an ordeal of exhausting waits and uncertainties. Access to targeted therapies, which could change the outcome of their battle, is hindered by bureaucratic and logistical delays, often forcing them to travel to distant centers or wait for weeks, even months, for crucial molecular diagnoses and the opinion of a multidisciplinary team.
The time lost waiting for genetic test results and discussion in a tumor board can be devastating, allowing the disease to progress undisturbed and depriving patients of valuable therapeutic opportunities.
This disparity in access is unacceptable: few centers of excellence offer advanced genomic panels and dedicated Molecular Tumor Boards, leaving thousands of patients without the possibility of truly personalized care close to home.
The result? Therapeutic decisions based on incomplete or outdated information and a "trial-and-error" approach that not only fails to provide answers but imposes unnecessary suffering, avoidable side effects, and extremely high costs—not just economic, but human.
For Doctors and Institutions (B2B)
From the perspective of doctors and healthcare institutions, the key problem is the information overload and increasing decision-making complexity. Tens of thousands of scientific oncology articles are published each year, guidelines are constantly updated, and new drugs and clinical trials continuously emerge.
18-25
Hours Required
For in-depth manual analysis of a complex oncology case
40-60%
Literature Coverage
Percentage of available scientific literature actually consulted
38%
Outdated Decisions
Of clinical decisions based on data older than 6 months
AI tools that have appeared on the market so far have shown significant limitations. For example, IBM Watson for Oncology or the knowledge base platforms of genomic companies tend to analyze only a subset of genetic mutations (covering ~65-75% of possible molecular data) or rigidly follow standard protocols without real personalization capabilities.
The Solution
An Integrated Ecosystem for Precision Oncology
Virtual Hospital
Simplified access, home sample collection, advanced multi-omics analysis
Molecular Tumor Board
International case discussion with global experts within 48-72 hours
AI Platform
Analysis of 4.5M publications and 380K clinical trials in real-time
Personalized Report
Evidence-based therapeutic recommendations and continuous support
B2C Solution: Lifetime Medendi Hospital
Lifetime Medendi's solution for patients is a virtual precision oncology hospital that eliminates geographical and temporal barriers to accessing personalized care.
Through an integrated platform, the patient (or their treating oncologist) can request a complete, turn-key service: from home tumor sample collection to in-depth genomic and multi-omic tumor profiling, up to the case discussion by an international Molecular Tumor Board and the delivery of a report with therapeutic recommendations within 48-72 hours.
This digital "one-stop shop" offers patients a streamlined and rapid experience: instead of waiting months hopping from one center to another, the patient receives a structured report within days that indicates potentially effective targeted therapies for their case (including opportunities to access experimental clinical trials) and provides their referring oncologist with clear guidance on a personalized treatment pathway.
B2B Solution: Medendi AI_D Platform
Medendi AI_D is a new generation solution for hospitals and oncologists, an intelligent platform capable of automatically analyzing an enormous quantity of scientific and clinical data and providing evidence-based suggestions specific to each clinical case.
Unlike existing tools, our solution overcomes the limitations of closed and static knowledge bases: Medendi AI_D continuously sifts through over 4.5 million scientific publications and 380,000 registered clinical trials, utilizing 12 specialized artificial intelligence algorithms.
It also integrates 42 genomic databases, validated real-world data from 120,000 patients, and complete profiles of approximately 6,800 oncological drugs. Thanks to this incomparably broad information coverage, Medendi AI_D provides exhaustive analysis updated in real-time: the system updates daily and sends personalized alerts within 24 hours of new discoveries relevant to monitored patients.
Technology
Cutting-Edge Innovation in AI and Diagnostics
B2C: Integrated Diagnostic Ecosystem
Medendi Hospital's technological offering revolutionizes access to precision oncology care. We have created an unprecedented diagnostic ecosystem where state-of-the-art tools merge into a fluid and intuitive user journey, ensuring speed, precision, and ease of use that redefines the patient experience.
Advanced NGS Panels: We utilize cutting-edge Next-Generation Sequencing (NGS) panels capable of in-depth analysis of up to 700 critical oncological genes, ensuring comprehensive and accurate molecular profiling of the tumor.
Precision Proteomic Analysis: Through innovative mass spectrometry, we perform detailed proteomic analysis, revealing the tumor protein profile essential for identifying emerging therapeutic targets.
Ultra-Sensitive MRD Monitoring: We employ tests for Minimal Residual Disease (MRD) based on circulating tumor DNA (ctDNA) sequencing, with unprecedented sensitivity to detect the slightest presence of residual disease post-treatment, crucial for early relapse detection.
Intuitive Software Platform: An interactive digital report, generated by our proprietary software platform, offers a clear and understandable summary of all analyses, enriched with detailed graphs and explanations, directly accessible to both the patient and the oncologist.
Collaborative MTB System: An advanced Molecular Tumor Board (MTB) system facilitates remote and secure collaboration among internationally renowned specialists, enabling rapid and informed multidisciplinary discussions.
The true technological power of our B2C solution lies in the integration and automation of every phase: from digitally tracked home sample collection kits to the most sophisticated bioinformatics pipelines for genomic analysis, up to the patient portal, where the personalized report is delivered with maximum clarity. Everything is designed to transform a scientifically complex process into an extraordinarily simple, fast, and effective user experience.
B2B: Advanced AI Architecture
Medendi AI_D technology is the innovative core of the company, the result of years of R&D in AI applied to medicine. Its architecture is designed to process and synthesize complex data with unprecedented speed and precision.
Scalable Data Collection
We implement an advanced and proprietary web crawling system that performs continuous and real-time monitoring of over 4.5 million scientific publications, 380,000 registered clinical trials, and 42 genomic databases. The knowledge base is dynamically updated every 24 hours to ensure the utmost topicality of information.
Advanced Semantic Analysis (NLP-LLM)
We utilize next-generation Natural Language Processing (NLP) and Large Language Models (LLM) for the automatic extraction of key information (e.g., biomarkers, drug targets, clinical outcomes) from millions of abstracts and full-texts. This data is then structured into medical knowledge ontologies for coherent and queryable semantic representation.
AI Decision Support Algorithms
Drug efficacy is estimated through an ensemble of artificial intelligence algorithms. These algorithms are trained on validated real-world data from 120,000 patients and comprehensive profiles of ~6,800 oncological drugs, providing robust and contextualized prediction scores.
Interactive Dashboard and Explainable AI
The platform offers an intuitive dashboard that presents prioritized outputs and does not just provide a suggestion, but justifies the recommendation through Explainable AI (XAI) mechanisms. Underlying scientific evidence, similarities with real clinical cases, and the reasons leading to the choice are displayed, ensuring transparency and trust in decision support.
Regulatory Compliance and Patent
Medendi AI_D is classified as a Class IIa Medical Device according to the European MDR (Medical Device Regulation), with CE certification. This attests to compliance with the highest safety and performance standards for clinical use. The innovative methodology is also protected by a filed patent, safeguarding intellectual property and competitive advantage.
Target Client
Multi-Segment Penetration Strategy
1
B2C: Target Patients
Our mission is to offer concrete hope and personalized solutions to patients who need them most. We address:
  • Patients with advanced or rare tumors: For those facing complex diagnoses where standard therapies show limitations, our precision analyses identify unique molecular alterations, unlocking access to targeted therapies that can radically transform the treatment path and significantly improve quality of life.
  • Families seeking clarity and support: We offer a qualified second opinion and a supported decision-making process to guide families through crucial choices, ensuring the selection of the most informed and personalized therapeutic strategy for their loved ones.
  • Oncologists eager to innovate: We provide specialists, including those not ultra-specialized in specific oncological pathologies, with essential tools to access cutting-edge knowledge and integrate the most innovative and targeted treatment options, optimizing care for their patients.
This segment represents a critical need and an extraordinary impact opportunity. In Italy, thousands of patients annually urgently await answers and solutions that only precision therapies can provide. We are here to make a difference, now more than ever.
2
B2B: Strategic Partners
  • Hospitals of Excellence
Eager for innovation, they serve as powerful testimonials.
  • Top Cancer Centers (e.g., IEO, MSKCC)
  • European centers (e.g., Gustave Roussy)
  • US hospitals with advanced oncological services
  • General Hospitals
They have a greater need for support in bibliographic research.
  • Large regional/university hospitals
  • Facilities with high volumes and less specialist support
  • Interested in ROI and time savings
  • Groups and Networks
Initial adoption can lead to widespread implementation to standardize protocols.
  • Private networks (e.g., Humanitas)
  • Large European groups and HMOs
  • Regional/national healthcare systems
Strategic Geographic Expansion
Initial focus on Italy (2026), expansion into Europe from 2027, and the United States from 2028. Future exploration of Asian markets.
Business Model
Diversified and Highly Scalable Revenues
B2C: Premium Fee-for-Service
Medendi Hospital operates with a premium paid healthcare service model, delivered as a 'package' per individual patient.
€3-5K
Price per clinical case
Complete package including tests, MTB, and report
€1.9K
MTB Cost
Price for consulting with healthcare facilities
30-60%
Gross Margin
At full capacity with economies of scale and optimization
This 'high-ticket' positioning reflects the high perceived added value (access to sophisticated tests and the world's best specialists) and the fact that it is often activated in critical situations, where the cost factor becomes secondary compared to the urgency of exploring all therapeutic options.
B2B: Hybrid Enterprise SaaS
Medendi AI_D follows an enterprise SaaS model with a mixed revenue structure: fixed annual license + variable usage-based component.
Annual License
Europe: €50,000/year for in-hospital use, including updates, support, and training
USA: $80,000/year for in-hospital use, including updates, support, and training
Fee per Clinical Case
Europe: €150/patient analyzed, aligning costs with actual usage and value generated
USA: $400/patient analyzed, aligning costs with actual usage and value generated
MTB as-a-Service
€1,900/case for hospitals that prefer to outsource complex cases
This combination ensures stable recurring revenues (fixed component) and upside linked to intensive adoption (variable component). The AI branch's EBITDA margin rises above 50% at full capacity, highlighting the typical profitability of software once initial fixed R&D costs are covered.
Go-to-Market
Phased and Targeted Launch Strategy
2026: Year Zero for Innovation and Certification
B2C: We initiate international expansion with strategic pilots in Spain and France, creating the first success stories in key markets.
B2B: We consolidate our foundation by implementing the solution in 1-2 pilot hospitals, alongside a pre-market experimental study. This is crucial for obtaining MDR certification and the FDA dossier, ensuring compliance and a competitive regulatory advantage that will open doors to the most demanding markets.
2027: The Commercial Acceleration of Medendi AI_D
B2C: Medendi AI_D takes flight with the goal of supporting approximately 120 crucial cases. We forge strategic partnerships with patient associations, amplifying our reach and building trust within the community.
B2B: We will penetrate 4-5 key EU markets, acquiring the first "lighthouse customers" who will be our ambassadors. Our credibility will be further strengthened by an impactful presentation at ESMO, targeting 9 installations that will demonstrate the unparalleled value of our technology.
2028: Strategic Conquest of the US Market
B2C: We expand our horizons by opening access to international patients, solidifying our reputation for excellence beyond borders.
B2B: After obtaining the prestigious FDA Clearance, 2028 marks our triumphant entry into the United States. We aim to collaborate with 5-6 top-tier American hospitals, establishing a strong local presence and undisputed recognition. Our ambitious goal: to achieve €7-8M in revenue, positioning ourselves as a leader in the sector.
2029: Consolidation and Global Leadership
B2C: Our model consolidates, with an anticipated impact on over 200+ cases per year, testifying to the trust and effectiveness of our solution.
B2B: We expect to have approximately 19 hospitals installed globally, generating a target of €12M in revenue. This year will also be dedicated to the development and introduction of new modules and the implementation of upselling strategies, ensuring sustainable growth and continuous innovation to maintain our market leadership.
Competitor Landscape
Defensible Competitive Advantage
IBM Watson for Oncology
Project fallen into disgrace. Recommendations too generic, lack of rapid updates, inability to manage rare cases. IBM has disinvested from healthcare AI.
Foundation Medicine
Automated report with a list of alterations and known drugs, without true clinical comparison. No support on "what to do" with the result. Coverage ~65-75% of molecular data.
Traditional Solutions
Manual literature searches require 18-25 hours per patient, cover <50% of relevant information, with 38% of decisions based on outdated data.
Intra-Group Collection and Financial Flow
€1.5M Strategic Capital for Lifetime Srl
€0.3M – Investment in Lifetime for International Expansion
1
2026 Objective
Activate Spain and France with a clear operational roadmap.
2
First Quarter
  • Mapping of clinical partners and laboratories.
  • Definition of collaboration agreements and verification of local regulatory requirements.
  • Go-to-Market Strategy: Framework agreements with hospital facilities, co-branding agreements, pricing aligned with local benchmarks, and full privacy compliance.
3
Second and Third Quarter
  • Launch of the first operational hubs with local partnerships for sample collection, logistics, reporting, and integration of the digital Molecular Tumor Board, with 48–72 hour SLAs.
  • Communication: Priority on KOL engagement, clinical white papers, and presence at specialized trade shows to build references.
4
From 2027
Progressive extension to other European countries, replicating the proven model.
In parallel, €1.2M of strategic capital will be financed by Lifetime to Medendi AI, with a targeted, milestone-based approach to maximize value.
Investment in Medendi AI
€1.2M - Technological, Regulatory, and Commercial Scaling
MDR and FDA Certifications
Critical Investment: €350,000
Key Actions for Success:
  • Collaboration with top experts for impeccable compliance.
  • Cutting-edge clinical tests to validate our superiority.
  • Prompt preparation and submission of documentation for MDR and FDA, ensuring our access to global markets.
  • Proactive maintenance of compliance for unhindered growth.
Time Horizon: 6-24 months of pure focus!
Revolutionary Milestones:
  • Obtaining the prestigious MDR certification (Class IIa/IIb), opening doors to Europe.
  • Submission of the 510(k) or De Novo pathway request to the FDA, for a decisive impact in the USA.
Technological Development and R&D
Growth Engine: €100k cash + 15% work for equity = approx. €400-500k equivalent
Work for equity includes the team developing the device
Impulses for the Future:
  • Continuous development and refinement of our AI algorithms for unmatched performance.
  • Implementation of revolutionary features that will redefine our platform.
  • Exploration and integration of emerging technologies (e.g., federated learning, explainable AI) to maintain our competitive edge.
First 12-18 Months: Acceleration
Upcoming Achievements:
  • Triumphant release of platform version 1.0.
  • Integration of 3 new predictive models, expanding our horizon.
  • Filing of 1 strategic patent, protecting our innovation.
Team and Human Resources
Investment in People: €200,000
Building the Team:
  • Hiring key talents: senior developers, data scientists, regulatory specialists, sales executives, marketing managers – the best to win!
  • Expansion of the operational and commercial team to scale without limits.
First 18 Months:
  • Completion of planned hires for the first year, building an unstoppable force.
  • Solid structuring of R&D and GTM teams, ready to conquer.
Infrastructure and Operations
Power Base: €50,000
Guarantees for Scalability:
  • Enhancement of our cloud infrastructure for unprecedented scalability and data security.
  • Unassailable HIPAA/GDPR compliance, protecting our most valuable data.
  • Acquisition of cutting-edge software licenses and development tools for optimal efficiency.
First 3-9 Months: Technological Solidity
Achieved Objectives:
  • Optimization of cloud costs for intelligent resource management.
  • Implementation of new IT security policies, safeguarding our future.
  • Upgrade of development tools for continuous innovation.
Pre-market Experimental Studies and Clinical Validation
Value Verification: €200,000
Paths to Excellence:
  • Conducting pilot studies and clinical trials in collaboration with the best hospital institutions.
  • Robust validation of the effectiveness and clinical impact of our solution, demonstrating our value.
  • Data collection for scientific publications that will attest to our leadership.
4-24 Months: Case studies and clinical research projects
Success Testimonials:
  • Initiation of 2 strategic clinical studies.
  • Publication of 1 peer-reviewed scientific article, for community recognition.
  • Presentation at 1 international medical conference.
Consolidated
Consolidated Results
Revenue
0.52 M€ (2025) → 19.59 M€ (2030)
CAGR 106%
EBITDA 2030
11.63 M€
(59.4%)
Cash Flow
CF 2030: 8.79 M€
Net Financial Position 2030: 15.02 M€
EBT > 0 from 2027; CF > 0 from 2026.
Investor Valuation and Return
Lifetime - B2C
Avg. EBITDA 29-30: 1.3 million
Multiplier: 7
Avg. Net Financial Position (NFP): +1.9 million
Equity value: 11 million
Medendi AI - B2B
Avg. EBITDA 29-30: 7.9 million
Multiplier: 15
Avg. Net Financial Position (NFP): +8.6 million
Equity value: 126 million
Group Valuation
Lifetime B2C - 11 million
85% Stake in Medendi AI - 107 million
15% work for equity with operational team

Lifetime → Medendi AI | Track Record, Status, and Investment Rationale
Origin and Positioning
Lifetime, owner of the Medendi brand, was established to address precision oncology along two main directions: patient care and support for oncologists in decision-making processes. We have measured actual diffusion, cultural and operational barriers, and informational needs within departments. This fieldwork led to the decision to develop an IT platform with AI verticals for clinical support, integrable into hospital workflows.
Financial and Operational Track Record
Approximately €2 million has been raised with existing investors. The company has achieved financial equilibrium and projects positive EBITDA from 2026. The governance and reporting structure is already geared towards execution metrics and cost control, with discipline on cash flow and development priorities.
Why Invest Now
This is not a pre-seed phase. There is an existing investor base, proven execution, and clinical traction.
The capital requested funds a clear path, with a shorter time-to-value and verifiable milestones in technology, adoption, and economic results.
Entering now allows investors to benefit from a favorable risk-return profile and an established product and regulatory roadmap.
Group Valuation
Assumptions
Lifetime B2C
Average EBITDA 2029–2030 approximately €1.3M, 7x multiple, average NFP +€1.9M. Rounded Equity value €11M.
Medendi AI
Stated Equity value €126M. The consolidated slide presents the growth and cash flow snapshot at full capacity.

Group Participation
Lifetime's Stake in B2B Post-Plan
85% of €126M = €107.1M
Total Group Value
(B2C + 85% of AI) = €11M + €107.1M = €118.1M

Methodological Note
For B2C, the calculation is explicit in the deck: EV = Average EBITDA 29–30 x 7; Equity = EV ± Average NFP. For AI, the same page directly states €126M as the equity value. Consistency with consolidated operating figures is referenced in the "Consolidated Vision" section of the deck.

Work for Equity for Key Collaborators
  • We allocate 15% to align incentives for those managing regulatory, product, and enterprise sales.
  • We avoid cash outlay and activate retention for scarce and highly sought-after profiles.
  • The 15% is sized to cover technical and commercial leadership and a credible future hire pool up to global product-market fit.
Impact
Beyond the Numbers: Transforming Lives and the Healthcare System
For Patients
  • Greater Treatment Opportunities: ~28% more therapeutic options identified for each patient
  • Timeliness: Reducing time from months to days increases the likelihood of effective intervention
  • Patient-Centered Comfort: Patients at the center with dedicated support and comprehensive coordination
  • Equitable Access: Same level of expertise everywhere, democratizing excellence
For the Healthcare System
  • Resource Optimization: Average savings of ~€10-15K per patient by avoiding ineffective therapies
  • Reduced Variability: Standardizing care levels upwards across all centers
  • Continuous Training: Platform serves as an on-the-job educational tool for doctors
  • Data and Research: Wealth of real-world data for new scientific discoveries
Ethical Dimension and the Future of Medicine
New Standard of Care
If successful, we will have demonstrated that a hybrid human-AI model provides better care. This could encourage others to adopt it, creating a paradigm shift in medicine. Just as it's unthinkable today not to use certain diagnostic tests, tomorrow it might become unthinkable to discuss a complex case without the aid of a platform like ours.
"Every patient saved or living longer thanks to us is an invaluable human success. Every euro saved for the system can be reinvested to treat others."
Stimulus for Innovation
Lifetime Medendi is one of the few examples in Italy of integration between healthcare and AI on a critical issue like cancer. If we succeed, we will be a case study that inspires other initiatives and attracts investments in the sector. We will likely become partners with universities for theses or research, helping to create new professional skills.
The impact therefore extends to the culture of innovation in our country and in Europe, with ripple effects that go beyond a single business.
15-20%
Increased Survival
Potential increase in 5-year survival for patients with rare or resistant cancers
€100M+
Potential NHS Savings
Annual savings for the Italian system if 10% of advanced patients follow optimized pathways
35%
Information Recovered
Clinically relevant data not integrated by current limited systems
Precision Oncology
What is Precision Oncology?

The Definition: Personalized Therapies
Precision oncology is a new approach to cancer treatment. It relies on personalized therapies, specifically designed for each patient and the unique characteristics of their tumor. Treatment decisions are no longer based solely on the tumor's type and stage.
The Key Concept: Tailored Treatment
The idea is simple: a "tailored" treatment for the patient works much better than standard, one-size-fits-all therapies. By analyzing the DNA of the tumor and the patient, doctors can discover specific genetic alterations or other unique "indicators."

How Does Precision Oncology Work?
In practice, precision oncology requires advanced testing and new ways of working, following a well-defined process:
1. Advanced Genetic Testing (NGS)
The use of specific genetic tests, known as NGS (Next Generation Sequencing), is crucial. These tests analyze the tumor's DNA, either from a small tissue sample (biopsy) or a simple blood draw (liquid biopsy). They look for hundreds of important genetic defects that characterize the tumor.
2. Data Analysis and Interpretation
These genetic data serve as the tumor's molecular "identity card." They are then analyzed by a multidisciplinary team of experts, called the Molecular Tumor Board. This team includes specialists such as oncologists, geneticists, and pharmacologists.
3. Personalized Therapy
The Molecular Tumor Board interprets the results of the NGS tests and suggests the most appropriate and personalized treatment for the patient. This approach allows doctors to understand in advance which treatment will be most effective, based on the tumor's specific "signals" (molecules and genes).

Key Benefits
Precision oncology combines a detailed molecular diagnosis of the tumor with targeted therapy, offering significant advantages:
Greater Effectiveness
It allows for the selection of the most suitable treatment for each individual patient, based on the unique characteristics of their tumor.
Reduction of Unnecessary Treatments
It helps to avoid ineffective treatments that would not work or would be too toxic, thereby improving the patient's quality of life.
What has changed with precision oncology?
Precision oncology is fundamentally different from traditional oncology. It changes how treatment decisions are made, the diagnostic tools used, the approach to patient management, the types of therapies available and the expected clinical outcomes.

Oncologia: Prima vs Oggi

Oncologia Tradizionale La cura si basava sul luogo di origine del tumore (es. polmone, colon) e sull'aspetto al microscopio. I pazienti con lo stesso tipo di tumore ricevevano spesso la stessa terapia standard ("uguale per tutti"). Oncologia di Precisione Non c'è un approccio "uguale per tutti". Si analizzano le caratteristiche specifiche di ogni tumore a livello molecolare. Le alterazioni genetiche uniche del tumore diventano il bersaglio di trattamenti personalizzati, con benefici migliori e più duraturi. In pratica, non si cura più genericamente un "tumore del colon" o un "tumore del polmone" nello stesso modo per tutti. Si cura invece il singolo paziente, scoprendo cosa rende il suo tumore unico e vulnerabile a livello molecolare, e agendo proprio su quelle caratteristiche.


1. La Diagnosi si Trasforma

Diagnosi Tradizionale Esami al microscopio (istopatologici) Tecniche di imaging (TAC, risonanze) Pochi altri test standard Diagnosi di Precisione Analisi approfondita del tumore: profilazione genomica estesa (NGS, pannelli multigenici) Ricerca di mutazioni genetiche: per farmaci mirati Biopsia liquida: esame del sangue per monitorare l'evoluzione molecolare Questa maggiore complessità diagnostica ha reso necessaria la collaborazione di molti specialisti diversi (per questo sono nati i "Molecular Tumor Board"). Richiede anche l'uso di tecnologie avanzate per analizzare il DNA, che non erano tipicamente impiegate nell'oncologia del passato.


2. Strumenti di Cura Innovativi

Oncologia Tradizionale Chirurgia Radioterapia Chemioterapia "generica": attacca tutte le cellule che si moltiplicano velocemente, con molti effetti collaterali. Oncologia di Precisione Molti farmaci "intelligenti" (terapie mirate): bloccano proteine specifiche o percorsi cellulari del tumore. Farmaci "agnostici": agiscono su anomalie genetiche specifiche, indipendentemente dall'organo. Immunoterapia: aiuta il sistema immunitario a combattere il cancro, basata su biomarcatori specifici. Per esempio, un nuovo farmaco chiamato trastuzumab-deruxtecan (che unisce un anticorpo a un medicinale) blocca la proteina HER2. Non viene usato solo per il tumore al seno che ha molta HER2, ma anche per qualsiasi altro tipo di tumore che produce troppa proteina HER2. Questa è una grande differenza rispetto al passato, quando un farmaco era creato e approvato solo per un tipo specifico di tumore. Anche l'immunoterapia fa parte della medicina di precisione. Viene usata quando specifici "segnalatori" (biomarcatori) nel tumore indicano che funzionerà. Ad esempio, i farmaci che bloccano PD-1/PD-L1 sono usati per vari tumori, ma sono più efficaci nei pazienti il cui tumore produce PD-L1 o ha molte mutazioni, perché questi pazienti di solito rispondono meglio alla cura.


3. L'Approccio Clinico al Paziente

Oncologia Tradizionale I medici seguivano protocolli standard. Gli stessi trattamenti per tutti i pazienti con lo stesso tipo e stadio di malattia, a meno di eccezioni. Meno dinamico. Oncologia di Precisione È molto più personalizzata e flessibile. Alcuni pazienti possono evitare la chemioterapia se i test genetici indicano terapie mirate più efficaci. Si combinano linee guida generali con risultati molecolari individuali. I pazienti possono essere inseriti in studi clinici ("basket trials"). Richiede una maggiore collaborazione tra diversi specialisti e aggiornamento costante.


4. Risultati Attesi Migliori

Maggiore Efficacia I trattamenti sono più efficaci e mirano a controllare la malattia più a lungo. Meno Effetti Collaterali Si riducono gli effetti collaterali non necessari, evitando trattamenti inutili per il paziente. Migliore Qualità di Vita Si trattano solo i pazienti che hanno reali possibilità di trarne beneficio, portando a migliori risultati e qualità di vita. In breve, l'oncologia di precisione mette il paziente al centro. Adatta la diagnosi e la cura alle sue caratteristiche individuali per trattamenti più rapidi ed efficaci. Questo porta a risultati clinici migliori e menos effetti collaterali rispetto alle terapie tradizionali.

Concrete Benefits for Oncology Patients
Numerous clinical studies demonstrate that precision oncology leads to real improvements for patients. These advancements impact both the efficacy and tolerability of treatments. Let's explore some of the main advantages, confirmed by recent data:
A Longer Life
Targeted therapies, based on the genetic characteristics of the tumor, can significantly extend life. A Stanford study showed that patients with advanced tumors treated with this approach lived almost twice as long compared to traditional chemotherapy (51.7 weeks versus 25.8 weeks). For advanced melanoma, the introduction of targeted therapies and immunotherapies has resulted in approximately one in two people being alive 10 years after diagnosis, a previously unimaginable outcome. This demonstrates that precision oncology increases survival even in advanced cancers.
Higher Probability of Tumor Reduction or Disappearance
Personalized therapies reduce tumors more frequently. In the ROME study, the percentage of measurable tumor reduction nearly doubled in the group receiving molecular therapies compared to standard therapy (17.5% versus 10%). In lung cancers with EGFR or ALK mutations, targeted drugs cause remissions in about 70% of cases, a result far superior to traditional chemotherapy. This means that hitting the "right target" more often leads to a significant decrease in tumor mass.
Fewer Side Effects and Improved Quality of Life
Precision oncology spares patients from unnecessarily toxic treatments, reducing severe adverse events and hospitalizations. Not administering ineffective therapies means fewer side effects. While precision drugs have their own effects, these are often different and sometimes more manageable than those of chemotherapy. Patients report a better quality of life and are often able to maintain daily activities for longer during therapy.
Economic Benefits for Hospitals and Healthcare Systems
Precision oncology not only brings clinical benefits to patients. It can also help hospitals and healthcare systems to save money and better utilize resources. It is true that innovative drugs and genetic tests are often expensive. However, several studies suggest that correctly applying personalized medicine can be sustainable, or even cost-effective, for public healthcare. This happens because it reduces ineffective treatments and avoids costly complications.
In other words, by avoiding treating patients who would not benefit from a therapy, unnecessary expenses are also avoided. Focusing care on the right patients, at the right time, allows for a more efficient use of hospital budgets.

Concrete Examples of Savings through Precision Oncology
Here are some concrete examples that show how precision medicine can lead to savings:
Reduced Costs and Improved Efficiency
Studies show that precision oncology reduces costs: the average weekly cost of care is 21% lower for genetically guided treatments (e.g., $2,720 vs $3,453). Furthermore, medical costs in the last 3 months of life are 6.9% lower for patients treated with targeted therapies, indicating fewer hospitalizations and aggressive interventions.
Fewer Costly Side Effects (DPD test)
Pre-therapy genetic testing for DPD enzyme deficiency in colon cancer prevents severe fluorouracil toxicity. The management of complications drops to €23,718 compared to €232,061 without the test. This avoids costs for long hospital stays and additional treatments.
More Targeted Care and Less Waste (French EGFR case)
The French program for testing EGFR mutations in lung cancer allowed only patients who would benefit from anti-EGFR therapy to be treated. Out of 24,558 hypothetical patients, only 2,532 were treated, avoiding the administration of an expensive drug to over 22,000 people for whom it would have been useless. This is estimated to save €101.3 million on unused drugs.
Genetic Tests and Reduction of Unnecessary Chemotherapy (Oncotype DX)
An Irish study on the use of the Oncotype DX genomic test for early-stage breast cancer helped avoid chemotherapy in 58% of cases. This generated a net saving of €793,565 in one year, freeing up resources and improving the quality of life for patients.
These specific examples confirm a key principle: treating the right patient, with the right therapy, at the right time is also economically advantageous. It avoids wasting resources on treatments that would not work. In the long term, the economic benefits can be enormous.

Large-Scale Economic Benefits
100B+ €
Socio-Economic Value
One study estimated that innovations in personalized medicine could generate "hundreds of billions" of euros in socio-economic value, thanks to longer lives, more productive people, and lower costs for serious diseases.
39 B $
Direct Savings for Healthcare Systems
The World Economic Forum calculates that gene therapies and personalized immunotherapies could lead to direct savings for healthcare systems of tens of billions (for example, an estimated $39 billion in four major Asia-Pacific countries).

Operational Advantages for Hospitals and Healthcare Systems
Optimized Resource Management
For hospitals and payers, precision oncology offers a way to better manage resources. For example, fewer unnecessary chemotherapy cycles free up beds and clinic time for other patients. Avoiding severe side effects reduces hospital days and costs associated with complications (such as intensive care or transfusions). Finding the most effective therapy for a patient quickly can also shorten the total course of treatment, using fewer services.
Initial Investment and Long-Term Benefits
Of course, achieving these benefits requires an initial investment in diagnostic technologies (such as advanced genetic analysis and informatics) and in staff training. But many healthcare systems are discovering that this investment brings concrete benefits over time.
The Importance of the ROME Study
A significant step towards making precision oncology a standard of care is the ROME study (the name stands for "Road to Oncological Medicine: from Histology to Target"). This clinical trial, conducted in Italy and whose results were published in Nature Medicine in 2025, is the first to clearly demonstrate, in a large number of patients, that a personalized approach against cancer is more effective than traditional therapies.

ROME Study Methodology
1
Patient Selection
The study involved 1,794 patients with advanced solid tumors who were no longer responding to standard treatments.
2
In-depth Molecular Analysis
For all patients, the tumor's genetics were thoroughly analyzed, both from tissue samples and from liquid biopsy, using advanced technologies.
3
Identification of "Actionable Alterations"
A group of experts examined the results to identify mutations or genetic targets treatable with specific drugs.
4
Randomization and Treatment
400 patients were divided into two groups: one group received personalized therapy ("tailored"), the other continued to receive the best standard therapy (traditional chemotherapy).

Key Clinical Results
17.5%
Objective Response Rate (ORR)
Percentage of patients with significant tumor reduction in the personalized therapy group. This data represents an increase of 7.5 percentage points compared to the 10% in the standard group, and is statistically significant.
3.5 months
Progression-Free Survival (PFS)
Average survival without disease worsening for the personalized group, versus 2.8 months for the standard group. This represents a 34% reduction in the risk of disease progression.
22%
PFS at 12 Months
Percentage of patients on targeted therapy without disease progression after 12 months, compared to 8.3% in the standard group. The personalized approach tripled the number of patients with long-term benefit.

Considerations on Overall Survival and Safety
Overall Survival (OS)
The ROME study showed similar overall survival values between the two patient groups. This is attributed to "crossover": more than half (approximately 52%) of the patients in the standard group, after disease progression, had the opportunity to switch to targeted therapy. This made a direct comparison on OS difficult, but achieving an advantage in PFS and ORR in a randomized study solidly confirms that precision oncology improves clinical outcomes compared to standard treatments.
Safety Profile
Regarding safety, ROME demonstrated that personalized therapies do not increase severe side effects. In fact, the percentage of serious adverse events (Grade 3-4) was slightly lower in the personalized therapy group (40%) compared to the control group (52%), although this difference was not statistically significant. This suggests that choosing the right drug for the right patient can also help reduce unnecessary side effects.

Strategic Importance of the ROME Study
Robust Scientific Confirmation
The study provides strong "Level II evidence" that a personalized, gene-based approach leads to real clinical benefits in many patients with advanced tumors, overcoming doubts generated by previous smaller studies (e.g., SHIVA study).
Replicable Practical Model
ROME demonstrates the feasibility of large-scale molecular screening (almost 1800 patients in ~3 years) and case management through a centralized Molecular Tumor Board, integrable into the national healthcare system. This model serves as a guide for the global implementation of precision oncology.
"Tumor-Agnostic" Strategy
The results support a "tumor-agnostic" precision oncology strategy. Personalized therapies, based on genetic analysis and multidisciplinary decisions, have the potential to significantly improve outcomes for patients with specific genetic alterations, regardless of the tumor's origin.
A New Standard
In conclusion, ROME is a fundamental step that reinforces the role of precision oncology as a new standard to pursue, encouraging further investment in future research (such as Phase III studies) to expand the knowledge and applications of this approach.
Europe: Precision Oncology Initiatives
In Europe, precision oncology is at the heart of coordinated health plans. Many national and international programs are investing resources to promote this approach.
European Union Strategies and Plans
Europe's Beating Cancer Plan
In 2021, the European Commission launched this plan with an investment of over 4 billion euros in initiatives for cancer prevention, diagnosis, and treatment. A key objective is to make personalized medicine more widespread: the aim is that by 2030, 90% of patients who need it will have access to specialized Comprehensive Cancer Centers across the EU.
Cancer Diagnostic and Treatment for All
This initiative was launched at the end of 2021 to promote the use of NGS technology for rapid and comprehensive tumor genetic analysis in all member states. Europe is laying the groundwork for advanced molecular testing and innovative treatments to be accessible to all patients, across all healthcare systems.

National Programs and European Regulation
United Kingdom
Concluded the 100,000 Genomes Project, analyzing the DNA of thousands of patients (many with cancer). The results are being used by the National Health Service (NHS) to improve future diagnoses and treatments.
France
Launched the "France Médecine Génomique 2025" plan in 2016, investing in the creation of national centers for DNA sequencing and reference points for oncological genomics.
Italy
AIOM (Italian Association of Medical Oncology) advocates for the establishment of "Molecular Tumor Boards" in all oncological hospitals to apply precision oncology in daily care. It also collaborates through networks like PerMed and Horizon Europe projects.
EMA - Drug Approval
The European Medicines Agency (EMA) is adapting its procedures to accelerate the approval of new biomarker-driven drugs. So far (by 2025), the EMA has approved two "tumor-agnostic" therapies – a number set to grow – unlike the numerous approvals already seen in the USA.
United States: Precision Oncology Programs and Regulations
In the United States, precision oncology has received significant momentum thanks to substantial public investment and regulations that foster innovation.

Key Research Initiatives
Precision Medicine Initiative (PMI) - 2015
Launched by President Obama, it initially invested approximately $215 million to accelerate research in personalized medicine.
Objective: To create the national "All of Us" database with genetic data from 1 million volunteers for large-scale studies.
National Cancer Moonshot - 2016
A federal program with an initial investment of $1 billion, led by then-Vice President Joe Biden.
Purpose: To "end cancer as we know it," aiming to achieve in 5 years progress that would typically take a decade. It boosted research, removed barriers (data sharing, public-private collaboration), and improved access to innovative treatments.
Example: The NCI-MATCH trial, which tested personalized treatments for tumors with specific genetic mutations, regardless of their origin.
Relaunch of the Cancer Moonshot - 2022
The U.S. government relaunched the program ("Moonshot 2.0") with even greater objectives:
  • Halving cancer deaths in the next 25 years
  • Improving the lives of patients during and after the disease.
It includes additional investments (NIH/NCI funds) and new policies to bring personalized care to everyone, through linked genetic databases, updated clinical pathways, and value-based reimbursement systems.

Regulation and Approval Pathways
FDA: Accelerated Approval of New Drugs
The FDA has implemented accelerated pathways (e.g., Breakthrough Therapy) for drugs intended for patients with specific genetic characteristics.
Thanks to this approach, from 2017 to date, the FDA has approved approximately ten "tumor-agnostic" therapies, effective for tumors with a specific genetic mutation, regardless of the organ of origin.
Examples: pembrolizumab (for microsatellite instability), larotrectinib and entrectinib (for NTRK gene fusion), RET inhibitors, BRAF V600E, etc.
Validation and Reimbursement of Diagnostic Tests
The FDA and CMS have launched programs to validate and reimburse companion diagnostics (such as complex genetic tests, e.g., FoundationOne CDx), which are essential for eligibility for targeted therapy.
In summary, in the USA, the regulatory and financial environment actively supports precision oncology, accelerating access to personalized therapies.
Global Precision Oncology Landscape
China: Ambitious Vision
China has launched a national precision medicine program (part of "Healthy China 2030") with funding of approximately $9 billion by 2030. The goal is to analyze the genome of up to 100 million people and develop new therapies. It has established a National Gene Bank and genome analysis centers that integrate genetic data into clinical cancer management.
Asia-Pacific: Regional Progress
Several Asia-Pacific countries are showing progress: Japan with a national cancer genomic medicine program (NGS testing), South Korea with investments in precision oncology centers, and Australia with pilot projects for genome analysis of advanced cancer patients.
450B
APAC Investments
billion dollars in the four main Asia-Pacific markets in research and related sectors over the next decade.
1.6T
Economic Growth
trillion dollars in total economic growth, thanks to technological advancements and improvements in population health.
39B
Healthcare Savings
billion dollars in avoidable healthcare costs in these four countries alone.
International Collaboration
Organizations like ICGC/TCGA and the Global Alliance for Genomics and Health promote the sharing of genetic data between countries. The World Health Organization has established an expert group on precision medicine, recognizing its potential to bridge gaps in care and make healthcare systems more sustainable.
Emerging Countries
In many emerging countries (such as India, Brazil, Middle Eastern states), projects are underway to bring molecular testing and targeted therapies to their populations, often in collaboration with Western research centers.
Global Trend
Despite ongoing inequalities in access (due to costs and infrastructure), the global trend is for precision oncology to become a priority, with significant public investments and regulatory adaptations to favor its application.
Global Precision Oncology Landscape
China: Ambitious Vision
China has launched a national precision medicine program (part of "Healthy China 2030") with funding of approximately $9 billion by 2030. The goal is to analyze the genome of up to 100 million people and develop new therapies. It has established a National Gene Bank and genome analysis centers that integrate genetic data into clinical cancer management.
Asia-Pacific: Regional Progress
Several Asia-Pacific countries show progress: Japan with a national program for cancer genomic medicine (NGS testing), South Korea with investments in precision oncology centers, and Australia with pilot projects for advanced cancer patient genome analysis.
450B
APAC Investments
billion dollars in the four main Asia-Pacific markets in research and related sectors over the next decade.
1.6T
Economic Growth
trillion dollars in total economic growth, thanks to technological advancements and improvements in population health.
39B
Healthcare Savings
billion dollars in avoidable healthcare costs in these four countries alone.
International Collaboration
Organizations like ICGC/TCGA and the Global Alliance for Genomics and Health promote genetic data sharing among countries. The World Health Organization has established an expert group on precision medicine, recognizing its potential to bridge care gaps and make healthcare systems more sustainable.
Emerging Countries
In many emerging countries (such as India, Brazil, Middle Eastern states), projects are underway to bring molecular tests and targeted therapies to their populations, often collaborating with Western research centers.
Global Trend
Despite persistent inequalities in access (due to costs and infrastructure), the global trend indicates that precision oncology is becoming a priority, with significant public investments and regulatory adaptations to favor its implementation.
Team and Scientific Committee
Catalyst for the Market and Pharma Channel
Trust Infrastructure: Our proposition is not just a SaMD that interprets data. It is a trust infrastructure grounded by an operational team and a Scientific Committee that have influence in key centers and pharmaceutical companies.
Recognized Authority: The rationale is simple: when clinical decision-makers recognize their peers in the board, adoption is not a leap of faith, it is continuity with the best international practice.
High Standard: Reputational capital makes Medendi AI a requirement for precision oncology.
Global KOL Committee: The Committee includes Key Opinion Leaders from global institutions such as MSKCC, MD Anderson, Vall d'Hebron, and IEO.

This composition grants Medendi AI a level of authority in the Italian landscape, solidifying our position as a leader in the sector.
Spotlight on Maurizio Scaltriti
Crucial Bridge
With experience at Memorial Sloan Kettering and AstraZeneca, he creates a vital link between tumor biology, clinical studies, and therapeutic adoption.
Scientific Direction
He defines the scientific direction of the board and guides priorities, backed by consolidated relationships with centers of excellence and industry leaders.
Translational Medicine
His role at AstraZeneca focuses on applying advanced technologies for clinical decisions, with an emphasis on biomarkers and rational therapeutic combinations.
Maurizio Scaltriti, Founder and Head of the Scientific Committee, is Vice President of Translational Medicine in Oncology at AstraZeneca.

Relevant Publication
"Not if, but when. Cancer: treatments today, treatments tomorrow" (Piemme, 2025)
This essay demystifies therapeutic development and the impact of precision medicine, reinforcing our board's positioning as an authoritative voice in the sector.
How the board shapes the product and clinical demand
The board's value extends beyond the prestige of its names. It provides a structured mechanism for directly listening to the needs of oncologists.

This process serves as a co-development laboratory, where emerging needs from real patients directly feed into the backlog for new features, explainability, and integrations required in the clinical setting.
Medendi AI operates on a vast and dynamic informational foundation, impossible for a single department to manage. It ensures continuous updates and precise explanations of recommendations, keeping the platform consistently aligned with the pace of scientific literature. This is how we transform weak signals into concrete and immediately applicable therapeutic choices.
4.5M Scientific Publications
380K Active Clinical Trials
42 Genomic Databases
120K Real-world Patients
Go-to-Market Enabled by People, Not Just the Algorithm
Our network ensures a strategic and credible entry into hospital systems. The operational plan includes European lighthouse sites, validations presented at ESMO, and a progressive expansion to the United States after regulatory clearance is obtained.
Low economic impact 'pay-per-use' pricing model that removes budget friction and accelerates SaMD adoption.
Acceleration of SaMD adoption and unprecedented integration into clinical practice.
European lighthouse sites, validations presented at ESMO, and progressive expansion to the United States after regulatory clearance.
MTB as a Service: The Strategic Revolution for Precision Medicine
Our MTB as a Service offering is not merely a service; it is your gateway to an unparalleled competitive advantage. We enable centers without an internal Molecular Tumor Board to instantly access world-class expertise, transforming every case into an opportunity for cutting-edge care.

In the dynamic healthcare landscape, the word-of-mouth of a Key Opinion Leader is invaluable. But having the most influential opinion leaders not just at our table, but alongside us in co-creation and validation—this is our unparalleled strategic advantage.
Strategic Economic Impact on Partner Hospitals
The synergy between our team and the Molecular Tumor Board offers a compelling perspective to CEOs, Medical Directors, and department heads, ensuring measurable benefits in patient outcomes and operational efficiency.
18-25h
Optimized Timelines
Reduction in manual research time per case.
>50%
Expanded Research
Extension of scientific literature coverage.
0%
Relevant Decisions
Elimination of decisions based on outdated data.
Our platform and the board's expertise are designed to exceed these critical benchmarks, leading to a significant increase in therapeutic options and substantial average savings. These are essential drivers for investment committees and regional healthcare networks.

The classification and certification of AID as a Class IIb MDR SaMD significantly accelerates the trust curve for risk managers and Ethics Committees.
The Pharma Channel: A Natural and Strategic Extension
Our board's expertise, comprising specialists in early drug development and industry leaders, unlocks three distinct and significant revenue streams:
Patient Identification
Targeting and prioritization of qualified patients for clinical trials.
Real-World Evidence
Execution of advanced programs for the collection and analysis of Real-World Evidence (RWE) data.
Algorithmic Co-development
Collaboration in the development of algorithmic modules for the identification and validation of emerging biomarkers.
Our platform integrates a robust database with trial registries and an extensive bibliographic corpus. This ensures precise matching and the reporting of rare variants, which are of high value to pharmaceutical sponsors. The publication of multicentric results further strengthens our authority in the competitive industry landscape.

In summary, our Molecular Tumor Board not only optimizes clinical decisions but also creates concrete partnership opportunities with pharmaceutical companies, generating a clear commercial return and positioning AID as a key player in pharmaceutical innovation.
Operational Workflow, Challenges, and Medendi Innovation
A comprehensive journey through precision oncology: from diagnosis to personalized treatment, the challenges of the Italian healthcare system, and innovative solutions to overcome them.
01 Diagnosis and Sample Collection
Initial tumor diagnosis through standard clinical examinations. The tumor sample is collected and preserved for molecular analysis. Basic clinico-pathological parameters, such as stage and histology, are also characterized.
02 In-depth Molecular Profiling
Next-Generation Sequencing (NGS) tests are performed on tumor DNA to identify relevant genetic mutations. This comprehensive molecular analysis of the tumor is essential for guiding future therapeutic choices.
03 Multidisciplinary Evaluation (Molecular Tumor Board)
Molecular results are discussed by a committee of specialists (MTB). Their role is to interpret identified alterations and suggest targeted therapies or clinical trials. This leads to a personalized therapeutic recommendation based on scientific evidence.
04 Personalized Treatment
Based on the MTB's recommendation, a tailored treatment plan is defined. This may involve specific targeted drugs for identified mutations or enrollment in a clinical trial. The oncologist, in agreement with the patient, initiates the recommended therapy.
05 Ongoing Monitoring and Follow-up
After therapy initiation, the patient is continuously monitored to assess its effectiveness and detect any progression early. Clinical and molecular data are recorded for future decisions, ensuring continuous adaptation of treatment to the disease's evolution.
Decision-Making Challenges
Complex Decisions
Decisions in the MTB can be complex. Often, there are no specific guidelines for the combination of tumor/mutation found: MTBs are created precisely to fill these gaps and share experiences in situations where scientific evidence is scarce or unequivocal indications are lacking. The board must balance many variables: the predictive value of mutations (for example, distinguishing an "actionable mutation" with an available targeted drug from a variant of uncertain significance), the patient's clinical condition and previously administered therapies, the actual accessibility of the drug (approved by AIFA? Available off-label? Enrolment in a trial?), as well as economic and ethical considerations.
Timelines
Timelines can be critical: the effectiveness of the MTB depends on how quickly molecular results are obtained and discussed. In current hospital practice, the complete flow from NGS testing to collegial discussion often takes several weeks, and in some contexts can extend up to two months, slowing down the start of personalized therapy.
IT Infrastructure
Finally, an efficient IT infrastructure is needed to support this: all clinical and genomic data should be shared on a common platform, accessible to members even at different times, to allow collegial analyses even when teams are distributed. The lack of integrated digital tools complicates the decision-making workflow, but progress is being made on this front with the development of dedicated software for MTBs.

In summary, the Molecular Tumor Board is the pivotal body that ensures the wealth of a patient's molecular information translates into a concrete, tailored therapeutic strategy. Its effectiveness depends both on the quality of incoming data (accurate and complete profiling) and on the multidisciplinary expertise deployed to interpret it. Numerous international Comprehensive Cancer Centers have already successfully implemented MTBs, and in Italy too, AIOM guidelines and regional oncology network projects promote their establishment as an indispensable tool for bringing the benefits of precision medicine to the patient's bedside.
Main Difficulties in Italian Oncological Practice
Despite the potential of precision oncology, the daily reality of Italian oncology departments presents several critical issues that hinder its large-scale implementation. Here are the main difficulties:
Scarcity of Resources and Low Diffusion of Molecular Tests
Italy is among the last countries in Europe for the use and accessibility of multigene NGS tests. Only 67% of Italian patients have access to multi-biomarker NGS-based tests (the lowest percentage in Western Europe), and only 2% of these are integrated into standard clinical pathways. This is due to a lack of dedicated funding and clear guidelines for the use of NGS within the National Health Service (SSN).
Delays and Logistical Difficulties in Diagnostic Pathways
The process of obtaining a molecular profile and multidisciplinary consultation is lengthy and cumbersome. Few centers have NGS platforms and dedicated MTBs internally, forcing patients into obstacle courses with external referrals and long waiting times (weeks or months). This temporal latency compromises the effectiveness of therapies. Additionally, geographical disparities and complex bureaucratic procedures for reimbursements further slow down access to personalized care.
Technological Limitations and Data Fragmentation
Precision oncology requires adequate IT infrastructure to manage large volumes of genomic data. Many Italian hospitals do not have integrated computerized systems, with separate databases that do not "communicate" with each other, complicating the aggregation of patient information for the MTB. The absence of a shared central database and the shortage of updated NGS equipment or specialized technical personnel (bioinformaticians, geneticists) create further bottlenecks and delays.
Lack of Updates and Information Overload
Oncology is a rapidly evolving field, with a huge volume of new publications and trials. This makes it difficult for oncologists to stay constantly updated; it is estimated that many clinical decisions are based on outdated scientific data. This difficulty impacts precision oncology, which continuously sees new biomarkers and therapies emerge. Furthermore, there is a reported lack of specific training for medical personnel on genomic tests, which leads to an under-prescription of such tests. Greater updating and support tools for clinicians are needed.
All these critical issues lead to a suboptimal use of precision medicine in the Italian National Health Service, creating disparities in access to care and delaying the application of personalized therapies.
Lifetime Medendi (B2C)
Business plan 2025‑2030
Lifetime Medendi (B2C)
Break-even
Net profit >0 already in 2026. From there, profitability accelerates due to operating leverage.
Margins
Contribution Margin stable and improving, EBITDA from 12% to 33% by plan end. This is consistent with a high-ticket B2C offering supported by a digital process and international MTB.
Go-to-market
Marketing structurally 13-16% of revenue. Not cut, but optimized. Mandatory KPIs: CAC, LTV, conversion per channel.
People
Staff growth with discipline – around 10-11% of revenue when fully operational. The "light" 2026 is the absorption of 2025 setup costs.
Accounting Capex
Amortisation zeroes out from 2028. It is necessary to plan the new investment cycle 2029-2031 to support quality and scalability.
Volume Reality Check
2030 revenue 5.28M ⇒ ~1,050–1,760 cases/year at 3–5k ticket. This is aligned with the deck model and the 2026-2030 ramp-up needs to be explained with channels and partnerships.
Balance Sheet B2C
Assets

Equity and Liabilities
Equity reconstruction
Capital increase 2026 (£1.5M), then equity growth with profits up to £3.8M in 2030. Adequate and healthy equity.
Deleveraging
Loans from £602k to £11k. Risk profile decreases and financial charges are compressed.
Cash
£2.62M by end of 2030. Buffer for execution and M&A options or new service lines.

Financial assets
£1.214M by 2028. These are capital allocated to growth and regulatory/AI enablers as per the deck's use of proceeds. We clearly explain business case and expected milestones.
Cash Flow Statement B2C
Cash Flows
Operating
positive from 2026, accelerating up to ~£1.3M in 2030. This demonstrates the sustainability of the model.
Equity boost
the 2026 increase funds scaling, allows deleveraging and maintains ample liquidity.
Investing
targeted outflows 2027‑2028 consistent with financial assets.
Medendi AI – B2B
Business Plan 2025‑2030
Income Statement – Medendi AI
Economic: Software Leverages, the Curve is Steep
  • Break-even already in 2027; from there, the margin explodes: 2030 EBITDA = €9.9M. 2026 is physiologically in the red due to structure build-up and capitalised R&D.
  • Top line: SaaS grows from €1.45M (2027) to €14.3M (2030). Licenses and patient/MTB services add volume and clinical credibility.
  • Profitability: the sheet shows EBITDA/SaaS from 20% to 69%; on total revenue, we are ~35% in 2030. This is in line with an enterprise SaaS after commercial payback.
  • Structural costs: well "dosed". People at full capacity ~€1.55M; S&M and technical services are targeted, not inflated. We maintain a hiring cadence linked to ARR per FTE and CAC payback < 12 months.
  • Royalties and incentives: the "Sales HR Bonuses" line replicates variable costs. We will clarify the commission policy and any internalised royalties to avoid double readings.
Balance Sheet – Medendi AI
Assets

Equity and Liabilities
Balance Sheet: Strong Equity, No Debt, Abundant Cash
Capital
Three steps of €400k (2026-2028) bring share premium to €1.2M and enable regulatory and commercial execution. Total Equity rises to €12.9M by 2030.
Working Capital
Accounts receivable ≈ €2.87M by 2030; consistent with DSO ~37 days on turnover. Target to maintain < 45 days.
Liabilities and Cash
Liabilities are solely operational and tax-related; zero financing. Final cash €12.4M: a buffer for technical M&A, add-on modules, and USA go-to-market.
Cash Flow Statement – Medendi AI
01
Positive Operating Cash Flow from 2027
€7.5M in 2030.
02
Investments concentrated in 2028
–€1.18M in intangibles. Funded with equity and operational growth.
03
Cash Net Financial Position throughout the plan
No debt needed to scale: the software is self-financing.
Integrated Solution
Medendi AI_D: Integrated AI Solution in Precision Oncology
Medendi AI_D is an integrated artificial intelligence platform for precision oncology, designed to support oncologists in complex clinical decisions.
An advanced system combining semantic natural language processing NLP - LLM and machine learning algorithms.
It deeply analyzes each patient's genomic and molecular data to provide structured and up-to-date information.
It offers clinically relevant data on tumor genetic mutations, targeted therapies, and pertinent clinical trials.
Medendi AI_D bridges the gap between the vast amount of biomedical knowledge and daily clinical practice, addressing key challenges:
Information Overload
Provides only the most pertinent and structured information.
Decision Uncertainty
Supports the oncologist with in-depth analysis for more confident decisions.
Continuous Updates
Allows staying updated on the latest scientific evidence effortlessly.
It presents itself as a turnkey solution for integrating precision medicine into hospital routines, offering a level of analysis and therapeutic personalization previously unimaginable.
Advanced NLP - LLM Engine to Transform Unstructured Knowledge into Clinical Data
Cutting-Edge Technology
At the heart of Medendi AI_D is a new generation NLP engine, based on advanced Large Language Models (LLM), specifically trained on the oncology domain. This component is capable of interpreting unstructured texts – such as scientific publications, medical guidelines, or clinical reports – extracting clinically usable knowledge from them.
In practice, the AI analyzes biomedical articles and databases with "semantic" reading, recognizing key entities and relationships (such as mutated genes, molecular pathways, drugs, and study results) and converting them into structured data.
Tangible Outcomes
This means that information which would normally require a clinician hours of reading and synthesis is made immediately available on the platform in an organized and navigable format. For example, if a new scientific discovery emerges regarding a tumor biomarker, Medendi AI_D's NLP engine comprehends it and automatically links it to the relevant patients.
The result is a living database of clinical knowledge, combining the most authoritative global oncology sources and making them accessible in real-time at the point of care. This approach allows for the transformation of vast unstructured knowledge into concrete decision-making support, available to both highly specialized centers and oncology departments with limited resources.
Predictive Machine Learning for Therapeutic Response Estimation
Medendi AI_D integrates a powerful predictive machine learning module, a "therapeutic recommendation engine" trained on thousands of clinical cases. This advanced algorithm identifies which combinations of genetic alterations, patient characteristics, and drugs have led to the best outcomes, offering data-driven decision support.
Algorithmic Second Opinion
The platform provides an algorithmic "second opinion," estimating the probable effectiveness of available therapeutic options for each patient, indicating the therapy with the highest probability of success.
Data-Driven Decisions
This quantitative support allows clinicians to base their decisions on data-driven evidence specific to the case at hand, moving beyond experience and intuition.
Added Clinical Value
Choosing the therapy with the highest probability of effectiveness can improve outcomes and avoid unnecessarily toxic or ineffective treatments.

Preliminary Results: Estimated increase of 28% in identified therapeutic options and improvement in 5-year survival by 17%.
Ultimately, Medendi AI_D's machine learning acts as an amplifier of clinical expertise, assisting oncologists in guiding choices towards more targeted and effective interventions, ranking therapeutic strategies by their expected benefit probability.
Continuous Monitoring of New Scientific Evidence and Patient Clinical Status
The Medendi AI_D platform offers proactive and continuous monitoring of new scientific evidence and the patient's clinical status. In oncology, where approximately 28,909 oncology studies were active in 2025, staying up-to-date is an unsustainable challenge for individual clinicians.
1
Automated Monitoring Engine
A "monitoring engine" acts as a radar, constantly surveying scientific and clinical sources to promptly intercept new publications, drugs, or guidelines relevant to the specific case.
2
Personalized Monitoring Profile
For each patient, a monitoring profile is created based on mutations and clinical characteristics. In the event of new evidence, the system generates a proactive alert to the clinician.
3
Integration with Hospital Systems
Medendi AI_D interfaces with hospital systems to acquire real-time updates on the patient's clinical picture. The AI re-evaluates and recalculates therapeutic recommendations based on this new information.
Overall Benefit
This approach relieves the oncologist from the burden of constant manual updating, reducing the risk of missing up to 70% of significant new publications. This leads to an increased chance for the patient to receive the most innovative and appropriate therapies.
Continuous monitoring ensures that therapeutic decisions remain optimal over time, always offering a plan based on the most up-to-date state of the art.
The Platform as a "Clinical Operating System" for Molecular Tumor Boards
Medendi AI_D is not merely a vertical software solution, but rather positions itself as a true "clinical operating system" for Molecular Tumor Boards – the multidisciplinary committees responsible for defining personalized therapies in complex oncological cases.
Integrated Digital Environment
The platform has been designed considering the collaborative workflow typical of these molecular boards, where oncologists, molecular biologists, pathologists, and other specialists share information to decide the therapeutic path for patients with specific genetic alterations.
Medendi AI_D offers an integrated digital environment where the Molecular Tumor Board can operate with maximum effectiveness: all patient data (clinical, pathological, genomic) are collected and displayed in intuitive dashboards; relevant scientific evidence (publications, trial results, updated guidelines) is made available contextually via NLP.
Orchestration of the Decision-Making Process
The therapeutic recommendations based on predictive AI are presented to the team with explanations of the rationale and confidence scores; finally, the monitoring module continues to inform the board about post-meeting updates.
Essentially, the platform orchestrates the decision-making process of the tumor board, ensuring that every member has the same updated informational basis and advanced tools for case analysis. This integrated approach leads Medendi AI_D to configure itself as a central hub – indeed, a clinical operating system – on which key applications for precision oncology run within the hospital.

Software-as-a-Service Model
From the perspective of the offering model, the solution is delivered as Software-as-a-Service (SaaS), which facilitates adoption by healthcare facilities: hospitals can activate the service with a subscription and gain immediate access to a complete "Molecular Tumor Board as a Service" including automatic updates and technical support. This formula allows for standardizing the approach to personalized oncology across multiple centers: for example, hospital groups or regional networks can implement Medendi AI_D in all their locations, ensuring a homogeneous level of quality and access to the best knowledge in every facility.
In summary, Medendi AI_D positions itself not as a simple tool, but as a fundamental clinical infrastructure for modern precision oncology, offering Molecular Tumor Boards a unified platform on which to base their therapeutic decisions with confidence and timeliness.
Regulatory Positioning as a Class IIb Medical Device (MDR)
Medendi AI_D is qualified as a Software as Medical Device (SaMD), falling within the definition of a medical device according to Regulation (EU) 2017/745 (MDR). Due to its support for diagnostic and therapeutic decisions in oncology, the platform is classified as Class IIb.
1
Preliminary Clinical Validation
Preliminary clinical validation in pilot hospitals for system accuracy and utility.
2
Comprehensive Technical Documentation
Comprehensive MDR technical documentation: risk management (ISO 14971), software design (IEC 62304), usability (IEC 62366), and data protection (GDPR).
3
Assessment with Notified Body
Conformity assessment with a Notified Body; implemented ISO 13485 Quality Management System.

Certification Timeline: CE marking as a Class IIb medical device expected by 2026.
This classification level implies a medium-to-high intrinsic risk, requiring a rigorous certification process with an independent Notified Body. Medendi AI_D adheres to all General Safety and Performance Requirements (GSPR) of the MDR to ensure patient safety and privacy.
Value of Certification
MDR Class IIb certification is a fundamental achievement that attests to Medendi AI_D's adherence to high European standards of safety and efficacy. It allows for commercialization on a European scale, strengthening scientific credibility and creating a competitive barrier. This path, which includes anticipated FDA approval, ensures safety and opens new opportunities for international collaborations for growth in strategic markets.
Adherence to the European AI Act for High-Risk Systems
Medendi AI_D complies with the European AI Act, which classifies medical AI systems, especially those integrated into Class IIa, IIb, or III devices, as "high-risk," imposing additional requirements.
Algorithmic Risk Management
A robust algorithmic risk management system has been implemented with data quality controls to prevent bias and establish data governance procedures.
Traceability and Transparency
Recording and traceability functionalities for recommendations, enabling audit trails. Transparency regarding the assistive nature of the recommendations.
Explainable AI
The Explainable AI approach makes the factors considered by the algorithm comprehensible, maintaining clinician trust and ensuring human oversight.

The physician always remains the final decision-maker, with AI acting as support, not replacing human judgment and respecting the principle of effective human control.

Medendi aims to be among the first European entities to obtain full MDR + AI Act certification, leveraging the joint assessment provided by the AI Act.
This focus on emerging regulatory compliance demonstrates Medendi's commitment to responsible innovation, aligned with future ethical and safety standards for AI in healthcare.
Competitive Advantages for Hospitals, Clinicians, Healthcare Systems, and Investors
Adopting Medendi AI_D offers **numerous competitive advantages** for all stakeholders involved in the precision oncology pathway:
For Hospitals and Oncology Centers
  • Improves therapeutic efficacy and patient outcomes.
  • Reduces ineffective treatment lines and optimizes healthcare costs.
  • Standardizes personalized therapeutic approaches across the entire hospital network.
  • Positions the institution at the forefront of AI utilization in oncology.
For Clinicians (Oncologists and Multidisciplinary Teams)
  • Acts as a virtual assistant, reducing cognitive load.
  • Saves 18-25 research hours per case, covering 100% of sources.
  • Offers a constant, data-driven "second opinion".
  • Ensures continuous updating of scientific evidence.
  • Democratizes innovation, making high-level expertise accessible even to peripheral centers.
For Healthcare Systems and Public/Private Payers
  • Generates a significant systemic impact.
  • Offers clinical and economic ROI: 40% clinical time saved and +28% therapeutic options identified.
  • Reduces the "trial-and-error" method in therapy selection.
  • Improves resource utilization and patient value.
  • Fosters collaborative networks and the creation of national registries.
  • Standardizes care pathways and reduces inequalities in access to innovative treatments.
Competitive Advantages for Hospitals, Clinicians, Healthcare Systems, and Investors
Adopting Medendi AI_D offers numerous competitive advantages for all stakeholders involved in the precision oncology pathway:
For Hospitals and Oncology Centers
  • Improves therapeutic efficacy and patient outcomes.
  • Reduces ineffective treatment lines and optimizes healthcare costs.
  • Standardizes personalized therapeutic approaches across the entire hospital network.
  • Positions the institution at the forefront of AI utilization in oncology.
For Clinicians (Oncologists and Multidisciplinary Teams)
  • Acts as a virtual assistant, reducing cognitive load.
  • Saves 18-25 hours of research per case, covering 100% of sources.
  • Provides a constant, data-driven "second opinion".
  • Ensures continuous updating of scientific evidence.
  • Democratizes innovation, making high-level expertise accessible even to peripheral centers.
For Healthcare Systems and Public/Private Payers
  • Generates significant systemic impact.
  • Offers clinical and economic ROI: 40% clinical time saved and +28% therapeutic options identified.
  • Reduces the "trial-and-error" method in therapy selection.
  • Improves resource utilization and patient value.
  • Fosters collaborative networks and the creation of national registries.
  • Standardizes care pathways and reduces disparities in access to innovative treatments.
Capital Increase Process (Aucap) – Timeline of Key Phases
Pre-money valuation: €7.8 million
1
December 11, 2025
Shareholders' Meeting Resolution: Approval of the transaction and definition of terms.
2
Within 30 days
Option subscription period: Exercise of option rights by existing shareholders.
3
Within 45 days from option deadline
Subscription of unexercised rights: Placement of remaining shares to qualified third-party investors.
4
End of February 2026
Transaction closing: Completion of capital increase and share capital increment.
Investor Valuation and Return
Lifetime - B2C
Average EBITDA 29-30: 1.3M
Multiplier: 7
Average Net Financial Position: +1.9M
Equity value: 11M
Medendi AI - B2B
Average EBITDA 29-30: 7.9M
Multiplier: 15
Average Net Financial Position: +8.6M
Equity value: 126M
Group Valuation
Lifetime B2C - 11M
85% Stake in Medendi AI - 107M
15% work for equity with operational team

Lifetime → Medendi AI | Track, Status and Investment Rationale
Origin and Positioning
Lifetime, owner of the Medendi brand, was created to address precision oncology along two main lines: patient care and supporting oncologists in their decision-making processes. We have measured effective diffusion, cultural and operational barriers, and information needs in hospital departments. From this fieldwork, we decided to develop an IT platform with AI verticals to provide clinical support, integratable into hospital workflows.
Financial and Operational Track Record
Approximately €2M has been raised with existing investors. The company has reached financial equilibrium and anticipates positive EBITDA from 2026. The governance and reporting structure is already focused on execution metrics and cost control, with discipline on cash and development priorities.
Why Invest Now
This is not a pre-seed phase. There is an existing investor base, proven execution, and clinical traction.
The capital requested funds a clear path, with a shorter time-to-value and verifiable milestones on technology, adoption, and economic results.
Investing today allows you to benefit from a favourable risk-return profile and an already established product and regulatory roadmap.
Group Valuation
Assumptions
Lifetime B2C
Average EBITDA 2029–2030 approximately ~1.3, 7x multiple, average NFP +1.9. Equity value rounded to €11m.
Medendi AI
Stated equity value €126m. The consolidated slide shows the growth snapshot and cash at full capacity.

Group Participation
Lifetime Stake in B2B post-plan
85% of €126m = €107.1m
Overall Group Value
(B2C + 85% of AI) = €11m + €107.1m = €118.1m

Methodological Note
For B2C, the calculation is explicit in the deck: EV = Average EBITDA 29–30 x 7; Equity = EV ± Average NFP. For AI, the same page directly reports €126m as the equity value. Consistency with consolidated operating numbers is referenced in the "Consolidated Vision" section of the deck.

Work for Equity for Key Collaborators
  • We allocate 15% to align incentives for those executing regulatory, product, and enterprise sales.
  • We avoid cash outlay and enable retention for scarce and highly sought-after profiles.
  • The 15% is sized to cover technical and commercial leadership and a credible future hire pool up to global product-market fit.
Impact
Beyond the Numbers: Transforming Lives and the Healthcare System
For Patients
  • Greater treatment options: ~28% more therapeutic options identified for each patient
  • Timeliness: Reduction of time from months to days increases the probability of effective intervention
  • Patient-centricity and comfort: Patients at the centre with dedicated support and complete coordination
  • Equity of access: Same level of expertise everywhere, democratisation of excellence
For the Healthcare System
  • Resource optimisation: Average savings of ~€10-15K per patient by avoiding ineffective therapies
  • Variability reduction: Standardising levels of care upwards across all centres
  • Continuous training: Platform serves as an on-the-job educational tool for doctors
  • Data and research: Wealth of real-world data for new scientific discoveries
Ethical Dimension and the Future of Medicine
New Standard of Care
If we succeed, we will have demonstrated that a hybrid human-AI model provides better care. This could encourage others to adopt it, creating a paradigm shift in medicine. Just as it is unthinkable today not to use certain diagnostic tests, tomorrow it could become unthinkable to discuss a complex case without the aid of a platform like ours.
"Every patient saved or living longer thanks to us is an invaluable human success. Every euro saved for the system can be reinvested to treat others."
Stimulus for Innovation
Lifetime Medendi is one of the few examples in Italy of integration between healthcare and AI on a critical issue such as cancer. If we succeed, we will be a case study that inspires other initiatives and attracts investment in the sector. We will probably become partners with universities for theses or research, contributing to creating new professional roles.
The impact therefore also extends to the culture of innovation in our country and in Europe, with ripple effects that go beyond the individual business.
15-20%
Increased Survival
Potential 5-year survival increase for patients with rare or resistant tumours
€100M+
Potential NHS Savings
Annually for the Italian system if 10% of advanced patients followed optimised pathways
35%
Information Recovered
Clinically relevant data not integrated by current limited systems